alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
This schedule contains summary financial information extracted from the
balance sheets and statements of operations found on page 2 and 4 of the
Company's Form 10-Q for the year to date, and is qualified in its entirety by
reference to such financial statements.
</LEGEND>
<PERIOD-TYPE>                         6-MOS
<FISCAL-YEAR-END>                   DEC-31-1997
<PERIOD-END>                        JUN-30-1998
<CASH>                                  320,355
<SECURITIES>                          2,475,517
<RECEIVABLES>                         1,256,989
<ALLOWANCES>                                  0
<INVENTORY>                           1,551,256
<CURRENT-ASSETS>                      6,432,876
<PP&E>                                4,919,921
<DEPRECIATION>                                0
<TOTAL-ASSETS>                       11,888,235
<CURRENT-LIABILITIES>                   658,696
<BONDS>                                       0
<COMMON>                             11,008,373
<PREFERRED-MANDATORY>                         0
<PREFERRED>                                   0
<OTHER-SE>                             (149,050)
<TOTAL-LIABILITY-AND-EQUITY>         11,888,235
<SALES>                               7,489,505
<TOTAL-REVENUES>                      7,489,505
<CGS>                                 5,507,440
<TOTAL-COSTS>                         5,507,440
<OTHER-EXPENSES>                      1,991,434
<LOSS-PROVISION>                              0
<INTEREST-EXPENSE>                            0
<INCOME-PRETAX>                          69,323
<INCOME-TAX>                             27,729
<INCOME-CONTINUING>                      41,594
<DISCONTINUED>                                0
<EXTRAORDINARY>                               0
<CHANGES>                                     0
<NET-INCOME>                             41,594
<EPS-PRIMARY>                              (.00)
<EPS-DILUTED>                              (.00)

</TABLE>
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.3300 Cytocentrifuge. ( a ) *Identification.* A cytocentrifuge is a centrifuge used to concentrate cells from biological cell suspensions (e.g., cerebrospinal fluid) and to deposit these cells on a glass microscope slide for cytological examination.
( b ) *Classification.* Class I (general controls). This device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 864.9.
[45 FR 60588, Sept. 12, 1980, as amended at 54 FR 25044, June 12, 1989; 66 FR 38789, July 25, 2001]
Exhibit 23

                          Independent Auditors' Consent

The Board of Directors
Anaren Microwave, Inc.:

We consent to  incorporation  by reference in the  Registration  Statements (No.
33-19618,  No.  33-1768,  No.  33-36761,  No.  333-03193,   No.  333-70397,  No.
333-70427,  No.  333-93739,  and No. 333-42646) on Form S-8 of Anaren Microwave,
Inc. of our report dated July 28,  2000,  relating to the  consolidated  balance
sheets of Anaren  Microwave,  Inc. and subsidiaries as of June 30, 2000 and June
30, 1999, and the related consolidated  statements of operations,  stockholders'
equity, and cash flows for each of the years in the three-year period ended June
30, 2000,  which report  appears in the June 30, 2000 annual report on Form 10-K
of Anaren Microwave, Inc.

                                                  /s/ KPMG LLP

Syracuse, New York
September 27, 2000
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3590 Preformed plastic denture tooth. ( a ) *Identification.* A preformed plastic denture tooth is a prefabricated device, composed of materials such as methyl methacrylate, that is intended for use as a tooth in a denture.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9.
[52 FR 30097, Aug. 12, 1987, as amended at 84 FR 71812, Dec. 30, 2019]
§ 1.1362-1 Election to be an S corporation. ( a ) *In general.* Except as provided in § 1.1362-5, a small business corporation as defined in section 1361 may elect to be an S corporation under section 1362(a). An election may be made only with the consent of all of the shareholders of the corporation at the time of the election. See § 1.1362-6(a) for rules concerning the time and manner of making this election.
( b ) *Years for which election is effective.* An election under section 1362(a) is effective for the entire taxable year of the corporation for which it is made and for all succeeding taxable years of the corporation, until the election is terminated.
[T.D. 8449, 57 FR 55449, Nov. 25, 1992]
# C_2014253EN.01003202.xml

| 4.8.2014 | EN | Official Journal of the European Union | C 253/32 |
| --- | --- | --- | --- |

4.8.2014

EN

Official Journal of the European Union

C 253/32

---

Action brought on 28 April 2014 — City Index/OHIM — Citigroup and Citibank (CITY INDEX)

(Case T-269/14)

2014/C 253/47

Language in which the application was lodged: English

Parties

Parties

Applicant: City Index Ltd (London, United Kingdom) (represented by: B. Brandreth, Barrister)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other parties to the proceedings before the Board of Appeal: Citigroup, Inc. and Citibank, NA (New York, USA)

Other parties to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Partially annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 19 February 2014 in case R 172/2013-2 that upheld the opposition in respect of goods and services in Classes 9, 16 and 36; |
| --- | --- |

—

Partially annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 19 February 2014 in case R 172/2013-2 that upheld the opposition in respect of goods and services in Classes 9, 16 and 36;

| — | Order the defendant to pay the applicant its costs incurred before the Board of Appeal and the General Court. |
| --- | --- |

—

Order the defendant to pay the applicant its costs incurred before the Board of Appeal and the General Court.

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: The applicant

Applicant for a Community trade mark:

Community trade mark concerned: The word mark ‘CITY INDEX’ for goods and services in Classes 9, 16, 36 and 41 — Community trade mark application No 7 4 58  094

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: Citigroup, Inc. and Citibank, NA

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: The figurative mark containing the word element ‘citi’ for goods and services in Classes 9, 16, 36 and 42, the community and national figurative marks containing the word elements ‘citifinancial’ and ‘citibank’, as well as the community and national word marks ‘CITICAPITAL’, ‘CITIMONEY’, ‘CITIFINANCIAL’, ‘CITI’, ‘CITIBOND’, ‘CITICONNECT’, ‘CITIBANK’ and ‘CITICARD’

Mark or sign cited in opposition:

Decision of the Opposition Division: The opposition was rejected

Decision of the Opposition Division:

Decision of the Board of Appeal: The decision of the Opposition Division was partially annulled and the Community trade mark application partially rejected

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 8(1)(b) of Regulation No 207/2009

Pleas in law:

---
§ 884.9 Limitations of exemptions from section 510(k) of the Federal Food, Drug, and Cosmetic Act (the act). The exemption from the requirement of premarket notification (section 510(k) of the act) for a generic type of class I or II device is only to the extent that the device has existing or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of in vitro diagnostic devices, only to the extent that misdiagnosis as a result of using the device would not be associated with high morbidity or mortality. Accordingly, manufacturers of any commercially distributed class I or II device for which FDA has granted an exemption from the requirement of premarket notification must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce for commercial distribution the device when: ( a ) The device is intended for a use different from the intended use of a legally marketed device in that generic type of device; e.g., the device is intended for a different medical purpose, or the device is intended for lay use where the former intended use was by health care professionals only;
( b ) The modified device operates using a different fundamental scientific technology than a legally marketed device in that generic type of device; e.g., a surgical instrument cuts tissue with a laser beam rather than with a sharpened metal blade, or an in vitro diagnostic device detects or identifies infectious agents by using deoxyribonucleic acid (DNA) probe or nucleic acid hybridization technology rather than culture or immunoassay technology; or
( c ) The device is an in vitro device that is intended: ( 1 ) For use in the diagnosis, monitoring, or screening of neoplastic diseases with the exception of immunohistochemical devices;
( 2 ) For use in screening or diagnosis of familial or acquired genetic disorders, including inborn errors of metabolism;
( 3 ) For measuring an analyte that serves as a surrogate marker for screening, diagnosis, or monitoring life-threatening diseases such as acquired immune deficiency syndrome (AIDS), chronic or active hepatitis, tuberculosis, or myocardial infarction or to monitor therapy;
( 4 ) For assessing the risk of cardiovascular diseases;
( 5 ) For use in diabetes management;
( 6 ) For identifying or inferring the identity of a microorganism directly from clinical material;
( 7 ) For detection of antibodies to microorganisms other than immunoglobulin G (IgG) or IgG assays when the results are not qualitative, or are used to determine immunity, or the assay is intended for use in matrices other than serum or plasma;
( 8 ) For noninvasive testing as defined in § 812.3(k) of this chapter; and
( 9 ) For near patient testing (point of care).
[65 FR 2319, Jan. 14, 2000]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.5260 Breathing circuit bacterial filter. ( a ) *Identification.* A breathing circuit bacterial filter is a device that is intended to remove microbiological and particulate matter from the gases in the breathing circuit.
( b ) *Classification.* Class II (performance standards).
[Federal Register Volume 75, Number 9 (Thursday, January 14, 2010)]
[Notices]
[Page 2137]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-520]


-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. EL09-57-002]


New York Independent System Operator, Inc.; Notice of Filing

January 5, 2010.
    Take notice that on December 31, 2009, New York Independent System 
Operator, Inc filed in compliance with the Commission's September 3, 
2009 Order, 128 FERC 61, 221 (2009) and the December 1, 2009 Extension 
of Time, revisions to Attachment S of its Open Access Transmission 
Tariff.
    Any person desiring to intervene or to protest this filing must 
file in accordance with Rules 211 and 214 of the Commission's Rules of 
Practice and Procedure (18 CFR 385.211, 385.214). Protests will be 
considered by the Commission in determining the appropriate action to 
be taken, but will not serve to make protestants parties to the 
proceeding. Any person wishing to become a party must file a notice of 
intervention or motion to intervene, as appropriate. Such notices, 
motions, or protests must be filed on or before the comment date. On or 
before the comment date, it is not necessary to serve motions to 
intervene or protests on persons other than the Applicant.
    The Commission encourages electronic submission of protests and 
interventions in lieu of paper using the ``eFiling'' link at http://www.ferc.gov. Persons unable to file electronically should submit an 
original and 14 copies of the protest or intervention to the Federal 
Energy Regulatory Commission, 888 First Street, NE., Washington, DC 
20426.
    This filing is accessible on-line at http://www.ferc.gov, using the 
``eLibrary'' link and is available for review in the Commission's 
Public Reference Room in Washington, DC. There is an ``eSubscription'' 
link on the Web site that enables subscribers to receive e-mail 
notification when a document is added to a subscribed docket(s). For 
assistance with any FERC Online service, please e-mail 
<a href="/cdn-cgi/l/email-protection#15535047565a7b797c7b70466065657a676155737067763b727a63"><span class="__cf_email__" data-cfemail="185e5d4a5b57767471767d4b6d6868776a6c587e7d6a7b367f776e">[email protected]</span></a>, or call (866) 208-3676 (toll free). For 
TTY, call (202) 502-8659.
    Comment Date: 5 p.m. Eastern Time on January 21, 2010.

Kimberly D. Bose,
Secretary.
[FR Doc. 2010-520 Filed 1-13-10; 8:45 am]
BILLING CODE 6717-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
(logo)****CURCIO

+COHEN

 

 

**Report of IndependentRegistered Public Accounting Firm**

 

Managing Member

Park Bridge Lender ServicesLLC

New York, NY

 

 

We have examinedmanagement’s assertion, included in the accompanying Management’sReport on Assessment of 2016 Compliance by Park Bridge Lender Services LLC withRegulation AB Servicing Criteria (“Management’s Report”),that Park Bridge Lender Services LLC (the “Company”) complied withthe servicing criteria set forth in Item 1122(d) of the U.S. Securities andExchange Commission’s Regulation AB as of and for the year ended December31, 2016, excluding those criteria noted as not applicable (N/A) within ExhibitB to Management’s Report. The transactions covered by this report areonly those transactions processed by the Company in its capacity as trustadvisor or operating advisor for the asset backed securities transactions (the“Platform”) identified in Management’s Report. ReferenceExhibit A to Management’s Report for the transactions covered by thisexamination. Management is responsible for the Company’s compliance withthe applicable servicing criteria. Our responsibility is to express an opinionon management’s assertion based on our examination.

 

Our examination was conductedin accordance with attestation standards of the Public Company AccountingOversight Board (United States) and, accordingly, included examining, on a testbasis, evidence about the Company’s compliance with the applicableservicing criteria and performing such other procedures as we considerednecessary in the circumstances. Our examination included testing of a selectedsample of the servicing activities related to the Platform, determining whetherthe Company performed those selected activities in compliance with theapplicable servicing criteria during the specified period. Our procedures werelimited to the selected transactions and servicing activities performed by theCompany during the period covered by this report. Our examination was notdesigned to detect material noncompliance arising from errors that may haveoccurred prior to or subsequent to our tests, that may have affected theCompany’s servicing activities during the period covered by this report.We believe that our examination provides a reasonable basis for our opinion.Our examination does not provide a legal determination on the Company’scompliance with the applicable servicing criteria.

 

In our opinion,management’s assertion that the Company complied with the aforementionedapplicable servicing criteria identified in Exhibit B to Management’sReport with respect to the transactions identified in Exhibit A toManagement’s Report as of and for the year ended December 31, 2016, forthe Platform, is fairly stated in all material aspects.

 

 

/s/ Curcio & Cohen,CPA’s, P.C.

 

 

New York, NY

February 2, 2017

 

 

CERTIFIED PUBLIC ACCOUNTANTSPC 7 PENN PLAZA, SUITE 1500 NEW YORK NY 10001

TEL: 212 557-9800  FAX:212 557 9819   WEBSITE: WWW.CWCCPAFIRM.COM
SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)    August 4, 2003

                               CNB HOLDINGS, INC.
--------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in its Charter)

    Georgia                           000-23991                 58-2362335
--------------------------------------------------------------------------------
(State or Other Jurisdiction         (Commission             (IRS Employer
of Incorporation)                    File Number)            Identification No.)

7855 Northpoint Parkway, Suite 200, Alpharetta, Georgia         30022-4849
--------------------------------------------------------------------------------
(Address of Principal Executive Offices)                        (Zip Code)

Registrant's telephone number, including area code    (770) 650-8262

--------------------------------------------------------------------------------
         (Former Name or Former Address, if Changed Since Last Report)
<PAGE>

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

      (c)   Exhibits

            99.1  Press Release of CNB Holdings, Inc. issued August 4, 2003.

Item 12. Results of Operation and Financial Condition.

      The information set forth under this Item 12 is being furnished and shall
not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.

      On August 4, 2003, CNB Holdings, Inc. issued a press release reporting its
financial results for the second quarter ended June 30, 2003. A copy of the
press release is hereby attached as Exhibit 99.1 and incorporated herein by
reference.
<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                            CNB HOLDINGS, INC.
                                              (Registrant)


Dated: August 4, 2003                   By: /s/ H.N. Padget, Jr.
                                            ------------------------------------
                                                H.N. Padget, Jr., President and
                                                Chief Executive Officer
<PAGE>

                                  EXHIBIT INDEX

Exhibit No.     Description of Exhibit
-----------     ----------------------
99.1            Press release issued by CNB Holdings, Inc. on August 4, 2003
                regarding second quarter results
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1270 Exophthalmometer. ( a ) *Identification.* An exophthalmometer is a device, such as a ruler, gauge, or caliper, intended to measure the degree of exophthalmos (abnormal protrusion of the eyeball).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9.
[52 FR 33355, Sept. 2, 1987, as amended at 53 FR 35604, Sept. 14, 1988; 66 FR 38810, July 25, 2001]
§ 876.2050 Prostate lesion documentation system. ( a ) *Identification.* A prostate lesion documentation system is a prescription device intended for use in producing an image of the prostate as an aid in documenting prostate abnormalities previously identified during a digital rectal examination. The device uses pressure sensors and image reconstruction software to produce a prostate image that highlights regional differences in intraprostatic tissue elasticity or stiffness. The device is limited to use as a documentation tool and is not intended for diagnostic purposes or for influencing any clinical decisions.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Non-clinical and clinical performance testing must demonstrate the accuracy and reproducibility of the constructed image.
( 2 ) Appropriate analysis/testing must validate electromagnetic compatibility, electrical safety, thermal safety, and mechanical safety.
( 3 ) Appropriate software verification, validation, and hazard analysis must be performed.
( 4 ) All elements of the device that may contact the patient must be demonstrated to be biocompatible.
( 5 ) Methods and instructions for reprocessing of any reusable components must be properly validated.
( 6 ) The labeling must include specific information needed to ensure proper use of the device.
[80 FR 72900, Nov. 23, 2015]
**Exhibit 35.3**

OFFICER’S CERTIFICATE 

I, Karen Montbach, aManaging Director of Citibank, N.A. (the “Company”), hereby certify, with respect to the Pooling and Servicing Agreement, dated as of August 1, 2015 (the “Agreement”), by and among Citigroup Commercial Mortgage SecuritiesInc., as depositor, Wells Fargo Bank, National Association, as master servicer and custodian, LNR Partners, LLC, as special servicer, Park Bridge Lender Services LLC, as operating advisor, Citibank, N.A., as certificate administrator (the“Certificate Administrator”), and Deutsche Bank Trust Company Americas, as trustee, the following: 

1.     Areview of the Company’s activities as Certificate Administrator during the reporting period ending December 31, 2016 and its performance under the Agreement has been made under my supervision. 

2.    To the best of my knowledge, based on such review, as of and for the reporting period ending December 31, 2016,the Company has fulfilled all of its obligations under the Agreement in all material respects throughout the reporting period. 

This statement is given bythe undersigned as an authorized officer of the Company and not in the undersigned’s individual capacity. 

Date:    February 27,2017
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.5928 Soft (hydrophilic) contact lens care products. ( a ) *Identification.* A soft (hydrophilic) contact lens care product is a device intended for use in the cleaning, rinsing, disinfecting, lubricating/rewetting, or storing of a soft (hydrophilic) contact lens. This includes all solutions and tablets used together with soft (hydrophilic) contact lenses and heat disinfecting units intended to disinfect a soft (hydrophilic) contact lens by means of heat.
( b ) *Classification.* Class II (Special Controls) Guidance Document: “Guidance for Industry Premarket Notification (510(k)) Guidance Document for Contact Lens Care Products.”
[62 FR 30988, June 6, 1997]